Virus-like particles: Potential veterinary vaccine immunogens

Research in Veterinary Science

Volumn 93, Issue 2, 2012, Pages 553-559

  Liu, Fuxiao ^a,b   Ge, Shengqiang ^a,c   Li, Lin ^a   Wu, Xiaodong ^a   Liu, Zengshan ^b   Wang, Zhiliang ^a  

^a National Diagnostic Center for Exotic Animal Diseases   (China)

^b JILIN UNIVERSITY   (China)

^c YANGZHOU UNIVERSITY   (China)

Author keywords

Animal virus; Baculovirus; Immunogen; Self assembly; Veterinary vaccine; VLP

Indexed keywords

ANTIGEN; DRUG CARRIER; EPITOPE; INACTIVATED VIRUS VACCINE; LIVE VACCINE; MARKER VACCINE; NEUTRALIZING ANTIBODY; SUBUNIT VACCINE; VIRUS LIKE PARTICLE VACCINE; VIRUS VACCINE;

AFRICAN HORSE SICKNESS VIRUS; ANIMAL DISEASE; ANIMAL VIRUS; ANTIBODY RESPONSE; ANTIBODY TITER; AVIAN INFLUENZA; AVIAN INFLUENZA VIRUS; BACULOVIRUS EXPRESSION SYSTEM; BLUETONGUE; BLUETONGUE ORBIVIRUS; CALICIVIRUS INFECTION; CARDIOVIRUS INFECTION; CELLULAR IMMUNITY; DOSE RESPONSE; DRUG ANTIGENICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; ENCEPHALOMYOCARDITIS VIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOREGULATION; IMMUNOSTIMULATION; INFECTION CONTROL; INFECTION PREVENTION; INFLUENZA VIRUS A H9N2; NEWCASTLE DISEASE; NONHUMAN; PARVOVIRUS INFECTION; PORCINE PARVOVIRUS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; RIFT VALLEY FEVER; RIFT VALLEY FEVER BUNYAVIRUS; SINGLE DRUG DOSE; VACCINE PRODUCTION; VESIVIRUS; VETERINARY MEDICINE; VIRION; VIRUS CAPSID; VIRUS ENVELOPE; VIRUS LIKE AGENT;

ANIMALS; EPITOPES; VACCINES, VIRUS-LIKE PARTICLE; VIRAL VACCINES; VIRUS DISEASES; VIRUSES;

ANIMALIA; HEPATITIS B VIRUS; HUMAN PAPILLOMAVIRUS;

EID: 84863110253     PISSN: 00345288     EISSN: 15322661     Source Type: Journal    
DOI: 10.1016/j.rvsc.2011.10.018     Document Type: Review

References (76)

1. Ashrafi G.H., Piuko K., Burden F., Yuan Z., Gault E.A., Muller M., Trawford A., Reid S.W., Nasir L., Campo M.S. Vaccination of sarcoid-bearing donkeys with chimeric virus-like particles of bovine papillomavirus type 1. Journal of General Virology 2008, 89:148-157.
2. Avellaneda G., Mundt E., Lee C.W., Jadhao S., Suarez D.L. Differentiation of infected and vaccinated animals (DIVA) using the NS1 protein of avian influenza virus. Avian Diseases 2010, 54:278-286.
3. Bachmann M.F., Lutz M.B., Layton G.T., Harris S.J., Fehr T., Rescigno M., Ricciardi-Castagnoli P. Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes. European Journal of Immunology 1996, 26:2595-2600.
4. Bachmann M.F., Zinkernagel R.M. Neutralizing antiviral B cell responses. Annual Review of Immunology 1997, 15:235-270.
5. Baek J.O., Seo J.W., Kim I.H., Kim C.H. Production and purification of human papillomavirus type 33 L1 virus-like particles from Spodoptera frugiperda 9 cells using two-step column chromatography. Protein Expression and Purification 2011, 75:211-217.
6. Belyaev A.S., Roy P. Development of baculovirus triple and quadruple expression vectors: co-expression of three or four bluetongue virus proteins and the synthesis of bluetongue virus-like particles in insect cells. Nucleic Acids Research 1993, 21:1219-1223.
7. Branco L.M., Grove J.N., Geske F.J., Boisen M.L., Muncy I.J., Magliato S.A., Henderson L.A., Schoepp R.J., Cashman K.A., Hensley L.E., Garry R.F. Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever. Virology Journal 2010, 7:279.
8. Breard E., Belbis G., Hamers C., Moulin V., Lilin T., Moreau F., Millemann Y., Montange C., Sailleau C., Durand B., Desprat A., Viarouge C., Hoffmann B., de Smit H., Goutebroze S., Hudelet P., Zientara S. Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats. Vaccine 2011, 29:2495-2502.
9. Brun A., Barcena J., Blanco E., Borrego B., Dory D., Escribano J.M., Le Gall-Recule G., Ortego J., Dixon L.K. Current strategies for subunit and genetic viral veterinary vaccine development. Virus Research 2011, 157:1-12.
10. Buonaguro L., Tornesello M.L., Buonaguro F.M. Virus-like particles as particulate vaccines. Current HIV Research 2010, 8:299-309.
11. Buonaguro L., Tornesello M.L., Tagliamonte M., Gallo R.C., Wang L.X., Kamin-Lewis R., Abdelwahab S., Lewis G.K., Buonaguro F.M. Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses. Journal of Virology 2006, 80:9134-9143.
12. Casal J.I. Use of the baculovirus expression system for the generation of virus-like particles. Biotechnology and Genetic Engineering Reviews 2001, 18:73-87.
13. Chackerian B. Virus-like particles: flexible platforms for vaccine development. Expert Review of Vaccines 2007, 6:381-390.
14. Deo V.K., Tsuji Y., Yasuda T., Kato T., Sakamoto N., Suzuki H., Park E.Y. Expression of an RSV-gag virus-like particle in insect cell lines and silkworm larvae. Journal of Virological Methods 2011, 177:147-152.
15. Di Martino B., Marsilio F., Roy P. Assembly of feline calicivirus-like particle and its immunogenicity. Veterinary Microbiology 2007, 120:173-178.
16. Fehr T., Skrastina D., Pumpens P., Zinkernagel R.M. T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:9477-9481.
17. Freivalds J., Dislers A., Ose V., Pumpens P., Tars K., Kazaks A. Highly efficient production of phosphorylated hepatitis B core particles in yeast Pichia pastoris. Protein Expression and Purification 2011, 75:218-224.
18. French T.J., Marshall J.J., Roy P. Assembly of double-shelled, viruslike particles of bluetongue virus by the simultaneous expression of four structural proteins. Journal of Virology 1990, 64:5695-5700.
19. French T.J., Roy P. Synthesis of bluetongue virus (BTV) corelike particles by a recombinant baculovirus expressing the two major structural core proteins of BTV. Journal of Virology 1990, 64:1530-1536.
20. Gamvrellis A., Leong D., Hanley J.C., Xiang S.D., Mottram P., Plebanski M. Vaccines that facilitate antigen entry into dendritic cells. Immunology and Cell Biology 2004, 82:506-516.
21. Garcea R.L., Gissmann L. Virus-like particles as vaccines and vessels for the delivery of small molecules. Current Opinion in Biotechnology 2004, 15:513-517.
22. Georgens C., Weyermann J., Zimmer A. Recombinant virus like particles as drug delivery system. Current Pharmaceutical Biotechnology 2005, 6:49-55.
23. Grgacic E.V., Anderson D.A. Virus-like particles: passport to immune recognition. Methods 2006, 40:60-65.
24. Harris S.J., Gearing A.J., Layton G.T., Adams S.E., Kingsman A.J. Enhanced proliferative cellular responses to HIV-1 V3 peptide and gp120 following immunization with V3:Ty virus-like particles. Immunology 1992, 77:315-321.
25. Haynes J.R., Dokken L., Wiley J.A., Cawthon A.G., Bigger J., Harmsen A.G., Richardson C. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine 2009, 27:530-541.
26. Henderson L.M. Overview of marker vaccine and differential diagnostic test technology. Biologicals 2005, 33:203-209.
27. Inoue M. Protection against uterine cervical cancer by HPV vaccines. Uirusu 2008, 58:155-163.
28. Jennings G.T., Bachmann M.F. The coming of age of virus-like particle vaccines. Biological Chemistry 2008, 389:521-536.
29. Jennings G.T., Bachmann M.F. Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. Annual Review of Pharmacology and Toxicology 2009, 49:303-326.
30. Jeoung H.Y., Lee W.H., Jeong W., Shin B.H., Choi H.W., Lee H.S., An D.J. Immunogenicity and safety of the virus-like particle of the porcine encephalomyocarditis virus in pig. Virology Journal 2011, 8:170.
31. Kee G.S., Pujar N.S., Titchener-Hooker N.J. Study of detergent-mediated liberation of hepatitis B virus-like particles from S. cerevisiae homogenate: identifying a framework for the design of future-generation lipoprotein vaccine processes. Biotechnology Progress 2008, 24:623-631.
32. Lee D.H., Kwon J.S., Lee H.J., Lee Y.N., Hur W., Hong Y.H., Lee J.B., Park S.Y., Choi I.S., Song C.S. Inactivated H9N2 avian influenza virus vaccine with gel-primed and mineral oil-boosted regimen could produce improved immune response in broiler breeders. Poultry Science 2011, 90:1020-1022.
33. Lee D.H., Park J.K., Lee Y.N., Song J.M., Kang S.M., Lee J.B., Park S.Y., Choi I.S., Song C.S. H9N2 avian influenza virus-like particle vaccine provides protective immunity and a strategy for the differentiation of infected from vaccinated animals. Vaccine 2011, 29:4003-4007.
34. Liu L., Celma C.C., Roy P. Rift Valley fever virus structural proteins: expression, characterization and assembly of recombinant proteins. Virology Journal 2008, 5:82.
35. Ludwig C., Wagner R. Virus-like particles-universal molecular toolboxes. Current Opinion in Biotechnology 2007, 18:537-545.
36. Luo L., Li Y., Ha S.D., Kang C.Y. Hydrophilicity dependent budding and secretion of chimeric HIV Gag-V3 virus-like particles. Virus Genes 2007, 35:187-193.
37. Lynch A.G., Tanzer F., Fraser M.J., Shephard E.G., Williamson A.L., Rybicki E.P. Use of the piggyBac transposon to create HIV-1 gag transgenic insect cell lines for continuous VLP production. BMC Biotechnology 2010, 10:30.
38. Lynch S.E., Gilkerson J.R., Symes S.J., Huang J.A., Tatarczuch L., Hartley C.A. Equine rhinitis A virus-like particle expressing DNA vaccine induces a virus neutralising immune response in mice. Virus Research 2011, 158:294-297.
39. Maree S., Durbach S., Huismans H. Intracellular production of African horsesickness virus core-like particles by expression of the two major core proteins, VP3 and VP7, in insect cells. Journal of General Virology 1998, 79:333-337.
40. McAleer W.J., Buynak E.B., Maigetter R.Z., Wampler D.E., Miller W.J., Hilleman M.R. Human hepatitis B vaccine from recombinant yeast. Nature 1984, 307:178-180.
41. McClenahan S.D., Bok K., Sosnovtsev S.V., Neill J.D., Burek K.A., Beckmen K.B., Smith A.W., Green K.Y., Romero C.H. Expression and self-assembly of virus-like particles from two genotypes of marine vesiviruses and development of an ELISA for the detection of antibodies. Veterinary Microbiology 2010, 142:184-192.
42. McGinnes L.W., Pantua H., Laliberte J.P., Gravel K.A., Jain S., Morrison T.G. Assembly and biological and immunological properties of Newcastle disease virus-like particles. Journal of Virology 2010, 84:4513-4523.
43. Mebatsion T., Koolen M.J., de Vaan L.T., de Haas N., Braber M., Romer-Oberdorfer A., van den Elzen P., van der Marel P. Newcastle disease virus (NDV) marker vaccine: an immunodominant epitope on the nucleoprotein gene of NDV can be deleted or replaced by a foreign epitope. Journal of Virology 2002, 76:10138-10146.
44. Mena J.A., Kamen A.A. Insect cell technology is a versatile and robust vaccine manufacturing platform. Expert Review of Vaccines 2011, 10:1063-1081.
45. Morrison T.G. Newcastle disease virus-like particles as a platform for the development of vaccines for human and agricultural pathogens. Future Virology 2010, 5:545-554.
46. Murawski M.R., McGinnes L.W., Finberg R.W., Kurt-Jones E.A., Massare M.J., Smith G., Heaton P.M., Fraire A.E., Morrison T.G. Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology. Journal of Virology 2010, 84:1110-1123.
47. Naslund J., Lagerqvist N., Habjan M., Lundkvist A., Evander M., Ahlm C., Weber F., Bucht G. Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus. Virology 2009, 385:409-415.
48. Noad R., Roy P. Virus-like particles as immunogens. Trends in Microbiology 2003, 11:438-444.
49. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D.L., Kitchener H.C., Castellsague X., de Carvalho N.S., Skinner S.R., Harper D.M., Hedrick J.A., Jaisamrarn U., Limson G.A., Dionne M., Quint W., Spiessens B., Peeters P., Struyf F., Wieting S.L., Lehtinen M.O., Dubin G. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007, 369:2161-2170.
50. Palucha A., Loniewska A., Satheshkumar S., Boguszewska-Chachulska A.M., Umashankar M., Milner M., Haenni A.L., Savithri H.S. Virus-like particles: models for assembly studies and foreign epitope carriers. Progress in Nucleic Acid Research and Molecular Biology 2005, 80:135-168.
51. Pan Q., He K., Huang K. Development of recombinant porcine parvovirus-like particles as an antigen carrier formed by the hybrid VP2 protein carrying immunoreactive epitope of porcine circovirus type 2. Vaccine 2008, 26:2119-2126.
52. Pantua H.D., McGinnes L.W., Peeples M.E., Morrison T.G. Requirements for the assembly and release of Newcastle disease virus-like particles. Journal of Virology 2006, 80:11062-11073.
53. Peeters B.P., de Leeuw O.S., Verstegen I., Koch G., Gielkens A.L. Generation of a recombinant chimeric Newcastle disease virus vaccine that allows serological differentiation between vaccinated and infected animals. Vaccine 2001, 19:1616-1627.
54. Pejawar-Gaddy S., Rajawat Y., Hilioti Z., Xue J., Gaddy D.F., Finn O.J., Viscidi R.P., Bossis I. Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles. Cancer Immunology, Immunotherapy 2010, 59:1685-1696.
55. Pillay S., Meyers A., Williamson A.L., Rybicki E.P. Optimization of chimeric HIV-1 virus-like particle production in a baculovirus-insect cell expression system. Biotechnology Progress 2009, 25:1153-1160.
56. Plummer E.M., Manchester M. Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design. Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology 2010, 3:174-196.
57. Radford A.D., Coyne K.P., Dawson S., Porter C.J., Gaskell R.M. Feline calicivirus. Veterinary Research 2007, 38:319-335.
58. Rappocciolo G., Birch J., Ellis S.A. Down-regulation of MHC class I expression by equine herpesvirus-1. Journal of General Virology 2003, 84:293-300.
59. Roldao A., Mellado M.C., Castilho L.R., Carrondo M.J., Alves P.M. Virus-like particles in vaccine development. Expert Review of Vaccines 2010, 9:1149-1176.
60. Roy P. Genetically engineered structure-based vaccine for bluetongue disease. Veterinaria Italiana 2004, 40:594-600.
61. Roy P. Bluetongue virus: dissection of the polymerase complex. Journal of General Virology 2008, 89:1789-1804.
62. Roy P., Noad R. Virus-like particles as a vaccine delivery system: myths and facts. Human Vaccines 2008, 4:5-12.
63. Schirmbeck R., Bohm W., Reimann J. Virus-like particles induce MHC class I-restricted T-cell responses. Lessons learned from the hepatitis B small surface antigen. Intervirology 1996, 39:111-119.
64. Schwartz-Cornil I., Mertens P.P., Contreras V., Hemati B., Pascale F., Breard E., Mellor P.S., MacLachlan N.J., Zientara S. Bluetongue virus: virology, pathogenesis and immunity. Veterinary Research 2008, 39:46.
65. Sedlik C., Dridi A., Deriaud E., Saron M.F., Rueda P., Sarraseca J., Casal J.I., Leclerc C. Intranasal delivery of recombinant parvovirus-like particles elicits cytotoxic T-cell and neutralizing antibody responses. Journal of Virology 1999, 73:2739-2744.
66. Sedlik C., Saron M., Sarraseca J., Casal I., Leclerc C. Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:7503-7508.
67. Sela, M., Hilleman, M.R., 2004. Therapeutic vaccines: realities of today and hopes for tomorrow. Proceedings of the National Academy of Sciences of the United States of America 101 Suppl. 2, 14559.
68. Stanley M., Gissmann L., Nardelli-Haefliger D. Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines. Vaccine 26. Suppl. 2008, 10:K62-K67.
69. Tao P., Luo M., Zhu D., Qu S., Yang Z., Gao M., Guo D., Pan Z. Virus-like particle vaccine comprised of the HA, NA, and M1 proteins of an avian isolated H5N1 influenza virus induces protective immunity against homologous and heterologous strains in mice. Viral Immunology 2009, 22:273-281.
70. Villa L.L. Prophylactic HPV vaccines: reducing the burden of HPV-related diseases. Vaccine 24. Suppl 2006, 1:S23-S28.
71. Warfield K.L., Bosio C.M., Welcher B.C., Deal E.M., Mohamadzadeh M., Schmaljohn A., Aman M.J., Bavari S. Ebola virus-like particles protect from lethal Ebola virus infection. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:15889-15894.
72. Win S.J., Ward V.K., Dunbar P.R., Young S.L., Baird M.A. Cross-presentation of epitopes on virus-like particles via the MHC I receptor recycling pathway. Immunology and Cell Biology 2011, 89:681-688.
73. Wu C.Y., Yeh Y.C., Yang Y.C., Chou C., Liu M.T., Wu H.S., Chan J.T., Hsiao P.W. Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus. PLoS ONE 2010, 5:e9784.
74. Ye L., Lin J., Sun Y., Bennouna S., Lo M., Wu Q., Bu Z., Pulendran B., Compans R.W., Yang C. Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. Virology 2006, 351:260-270.
75. Yin S., Sun S., Yang S., Shang Y., Cai X., Liu X. Self-assembly of virus-like particles of porcine circovirus type 2 capsid protein expressed from Escherichia coli. Virology Journal 2010, 7:166.
76. Zhang L.F., Zhou J., Chen S., Cai L.L., Bao Q.Y., Zheng F.Y., Lu J.Q., Padmanabha J., Hengst K., Malcolm K., Frazer I.H. HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine 2000, 18:1051-1058.